Sacituzumab Govitecan In TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Invasive Breast Cancer|Triple Negative Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|HER2-negative Breast Cancer
Interventions: DRUG: Sacituzumab Govitecan|DRUG: Pembrolizumab
Sponsor: Aditya Bardia
Collaborators: Gilead Sciences